Spyre Therapeutics Future Growth
Future criteria checks 0/6
Spyre Therapeutics's revenue and earnings are forecast to decline at 23.3% and 7.8% per annum respectively while EPS is expected to grow by 11.7% per annum.
Key information
-7.8%
Earnings growth rate
11.7%
EPS growth rate
Biotechs earnings growth | 30.2% |
Revenue growth rate | -23.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 09 Aug 2024 |
Recent future growth updates
Recent updates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
Feb 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 0 | -199 | -152 | -120 | 5 |
12/31/2025 | 4 | -178 | -141 | -116 | 7 |
12/31/2024 | 3 | -169 | -165 | -131 | 7 |
6/30/2024 | N/A | -186 | -141 | -156 | N/A |
3/31/2024 | 1 | -364 | -96 | -111 | N/A |
12/31/2023 | 1 | -339 | -85 | -100 | N/A |
9/30/2023 | 1 | -294 | -72 | -87 | N/A |
6/30/2023 | 1 | -273 | -67 | -67 | N/A |
3/31/2023 | 1 | -78 | -72 | -72 | N/A |
12/31/2022 | 2 | -84 | -80 | -80 | N/A |
9/30/2022 | 6 | -85 | -81 | -81 | N/A |
6/30/2022 | 7 | -88 | -83 | -83 | N/A |
3/31/2022 | 20 | -72 | -61 | -60 | N/A |
12/31/2021 | 19 | -66 | -54 | -54 | N/A |
9/30/2021 | 15 | -68 | -53 | -52 | N/A |
6/30/2021 | 14 | -66 | -54 | -52 | N/A |
3/31/2021 | N/A | -80 | -77 | -74 | N/A |
12/31/2020 | N/A | -81 | -80 | -76 | N/A |
9/30/2020 | N/A | -80 | -79 | -75 | N/A |
6/30/2020 | N/A | -83 | -79 | -75 | N/A |
3/31/2020 | N/A | -80 | -74 | -72 | N/A |
12/31/2019 | N/A | -78 | -67 | -66 | N/A |
9/30/2019 | N/A | -72 | -57 | -57 | N/A |
6/30/2019 | N/A | -62 | -48 | -48 | N/A |
3/31/2019 | 2 | -53 | -41 | -41 | N/A |
12/31/2018 | 4 | -44 | -33 | -32 | N/A |
9/30/2018 | 5 | -36 | -31 | -31 | N/A |
6/30/2018 | 7 | -32 | -30 | -30 | N/A |
3/31/2018 | 6 | -29 | N/A | -27 | N/A |
12/31/2017 | 5 | -27 | N/A | -25 | N/A |
9/30/2017 | 5 | -26 | N/A | -23 | N/A |
6/30/2017 | 5 | -25 | N/A | -22 | N/A |
3/31/2017 | 5 | -23 | N/A | -20 | N/A |
12/31/2016 | 5 | -22 | N/A | -19 | N/A |
9/30/2016 | 5 | -20 | N/A | -15 | N/A |
6/30/2016 | 5 | -17 | N/A | -13 | N/A |
3/31/2016 | 7 | -13 | N/A | -12 | N/A |
12/31/2015 | 6 | -12 | N/A | -11 | N/A |
9/30/2015 | 5 | -11 | N/A | -13 | N/A |
6/30/2015 | 3 | -11 | N/A | -11 | N/A |
3/31/2015 | N/A | -12 | N/A | -8 | N/A |
12/31/2014 | N/A | -10 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYRE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SYRE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SYRE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SYRE's revenue is expected to decline over the next 3 years (-23.3% per year).
High Growth Revenue: SYRE's revenue is forecast to decline over the next 3 years (-23.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SYRE's Return on Equity is forecast to be high in 3 years time